Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARK4 | Q96L34 | 8/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.43 |
| ▸ | F12 | P00748 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28713931 | 0.81 | MARK4 (0.59) | MARK4PTGS1PTGS2KDM4EGAA | |
| SCHEMBL28561312 | 0.80 | MARK4 (0.64) | MARK4PTGS1PTGS2KDM4EMAPT | |
| SCHEMBL3072062 | 0.79 | PTGS1 (0.56) | PTGS1PTGS2KDM4EGAAMAPK1 | |
| SCHEMBL1728473 | 0.78 | PTGS2 (0.47) | MARK4PTGS1PTGS2KDM4EGAA | |
| Hydrochloric Acid SCHEMBL3777035 | 0.77 | MARK4 (0.46) | MARK4PTGS1PTGS2KDM4EGAA | |
| SCHEMBL10680637 | 0.75 | PTGS1 (0.64) | MARK4PTGS1PTGS2KDM4EGAA | |
| SCHEMBL11026812 | 0.74 | USP7 (0.60) | KDM4EGAAMAPK1HPGDRAD51 | |
| SCHEMBL3077074 | 0.74 | MAPK1 (0.47) | KDM4EGAAMAPK1HPGDMKNK1 | |
| SCHEMBL3070139 | 0.74 | KDM4E (0.47) | KDM4EGAAMAPK1MAPTHPGD | |
| SCHEMBL14005644 | 0.73 | MAPK1 (0.50) | KDM4EGAAMAPK1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2260033-B1 | 2-benzoylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof | SANOFI SA (FR) | 2011-11-23 | — | — | EP | claimed |
| US-20100317687-A1 | 2-BENZOYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | claimed |
| EP-2260033-B1 | 2-benzoylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof | SANOFI SA (FR) | 2011-11-23 | — | — | EP | disclosed |
| US-20100317687-A1 | 2-BENZOYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317687-A1 | 2-BENZOYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | XDH, REN, GLS | MARK4 4099/4885PTGS1 1046/4885PTGS2 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.